Who are Lioresal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xyrem, Low Sodium Oxybate, Sodium Oxybate (SMO), Baclofen ER, placebo + oral baclofen, PXT3003 dose 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/baclofen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lioresal — Competitive Intelligence Brief

Lioresal (BACLOFEN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: gamma-Aminobutyric Acid-ergic Agonist [EPC]. Area: Neuroscience.

marketed gamma-Aminobutyric Acid-ergic Agonist [EPC] GABA-B receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Lioresal (BACLOFEN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lioresal TARGET	BACLOFEN		marketed	gamma-Aminobutyric Acid-ergic Agonist [EPC]	GABA-B receptor	1977-01-01
Xyrem	Xyrem	Jazz Pharmaceuticals	marketed		Calcium/calmodulin-dependent protein kinase type II subunit alpha, GABA-B receptor, Gamma-hydroxybutyrate receptor
Low Sodium Oxybate	Low Sodium Oxybate	Leiden University Medical Center	marketed	GHB receptor agonist / GABA-B receptor agonist	GHB receptor, GABA-B receptor
Sodium Oxybate (SMO)	Sodium Oxybate (SMO)	Catholic University of the Sacred Heart	marketed	GABA-B receptor agonist; CNS depressant	GABA-B receptor
Baclofen ER	Baclofen ER	Alkermes, Inc.	marketed	GABA-B receptor agonist	GABA-B receptor
placebo + oral baclofen	placebo + oral baclofen	Shaare Zedek Medical Center	marketed	GABA-B receptor agonist	GABA-B receptor
PXT3003 dose 1	PXT3003 dose 1	Pharnext S.C.A.	phase 3	Fixed-dose combination / Immunomodulator	Multiple targets (baclofen: GABA-B receptor; naltrexone: opioid receptors; sorbitol: osmotic agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-09-08 — Lioresal · 11446246 · Method of Use · US
2037-09-29 — Lioresal · 11324696 · Formulation · US
2039-07-29 — Lioresal · 11654124 · Formulation · US
2039-07-29 — Lioresal · 10792262 · Formulation · US
2039-07-29 — Lioresal · 11931328 · Formulation · US
2039-08-30 — Lioresal · 10610502 · Method of Use · US
2041-09-29 — Lioresal · 11850225 · Formulation · US
2041-09-29 — Lioresal · 11491125 · Formulation · US

Sponsor landscape (gamma-Aminobutyric Acid-ergic Agonist [EPC] class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lioresal — Competitive Intelligence Brief. https://druglandscape.com/ci/baclofen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab